Integral Health Asset Management LLC Has $7.10 Million Stock Position in Sana Biotechnology, Inc. $SANA

Integral Health Asset Management LLC lifted its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 33.3% during the third quarter, HoldingsChannel reports. The firm owned 2,000,000 shares of the company’s stock after acquiring an additional 500,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in Sana Biotechnology were worth $7,100,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. TD Waterhouse Canada Inc. acquired a new position in Sana Biotechnology during the third quarter worth $37,000. Lyell Wealth Management LP acquired a new stake in Sana Biotechnology in the third quarter valued at $37,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Sana Biotechnology in the third quarter valued at $39,000. Russell Investments Group Ltd. bought a new position in shares of Sana Biotechnology in the 3rd quarter valued at about $39,000. Finally, Griffin Asset Management Inc. acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth about $41,000. 88.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SANA shares. HC Wainwright dropped their target price on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Zacks Research downgraded Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Morgan Stanley restated an “overweight” rating and issued a $12.00 price objective on shares of Sana Biotechnology in a research note on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.36 on Friday. The stock has a market cap of $896.68 million, a PE ratio of -3.46 and a beta of 1.96. The firm has a 50-day moving average of $4.16 and a 200-day moving average of $4.13. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). As a group, analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Sana Biotechnology Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.